Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial to be conducted at multiple Parkinson Study Group (PSG) sites in the
USA. Patients with early Parkinson disease will be randomly allocated to one of 4 arms in the
study. The 4 arms include 3 arms with different doses of aplindore MR tablets and 1 placebo
arm. The study drug will be taken twice a day (BID). The study is blinded and neither
subjects, nor the investigators, will know what treatment the subject is receiving.
Investigational study drug will be adjusted to the assigned dosage and then maintained at
that dosage for the balance of the 12 week follow-up period. The entire study will take about
13 weeks. The study will assess the safety and tolerability of aplindore and measure how
effective aplindore is in improving movement and other effects of Parkinson disease.